Prothena Corp. Plc Stock News

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September...

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program.

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker-than-expected performance, with GAAP EPS of -2.34 missing the analysts' estimate of -1.25 and a much larger GAAP net loss than anticipated.

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.

DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.